Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27521446.
- Also identified by PMC identifier 5154749.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Breast Cancer Index appears to perform better than the 21-gene recurrence score in predicting 10-year disease-free survival in postmenopausal women with hormone receptor-positive lymph node-negative early-stage breast cancer. This may have implications for clinical use of first-generation versus second-generation multiparametric genomic assays. Clin Cancer Res; 22(20); 4963-5. ©2016 AACRSee related article by Sestak et al., p. 5043.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Antineoplastic Combined Chemotherapy Protocols
- Biological Assay
- Breast Neoplasms
- Nitriles
- Tamoxifen
- Triazoles